In this Review, the authors provide an overview of the evidence regarding the use of blood levels of glial fibrillary acidic protein as a biomarker in a range of neurological diseases, including traumatic brain injury, stroke, multiple sclerosis and Alzheimer disease.
- Ahmed Abdelhak
- Matteo Foschi
- Hayrettin Tumani